Diagnostic accuracy of HPV16 early antigen serology for HPV‐driven oropharyngeal cancer is independent of age and sex

Kusters, J. M. A. et al. (2024) Diagnostic accuracy of HPV16 early antigen serology for HPV‐driven oropharyngeal cancer is independent of age and sex. International Journal of Cancer, 154(2), pp. 389-402. (doi: 10.1002/ijc.34710) (PMID:37694289)

[img] Text
309475.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

2MB

Abstract

A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels.

Item Type:Articles
Additional Information:Associazione Italiana per la Ricerca sul Cancro, Grant/Award Number: CPDA057222;Canadian Cancer Society Research Institute; Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme, Grant/Award Number: C18281/A19169; Division of Cancer Prevention, National Cancer Institute, Grant/Award Number:R01-CA90731; European Commission, Grant/Award Number: QLK1-2001-00182;National Institute for Health Research, Grant/Award Number: RP-PG-0707-10034;National Institute of Dental and Craniofacial Research, Grant/Award Number: R01DE025712; National Institutes of Health.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Conway, Professor David
Creator Roles:
Conway, D.Data curation
Authors: Kusters, J. M. A., Diergaarde, B., Ness, A., Schim van der Loeff, M. F., Heijne, J. C. M., Schroeder, L., Hueniken, K., McKay, J. D., Macfarlane, G. J., Lagiou, P., Lagiou, A., Polesel, J., Agudo, A., Alemany, L., Ahrens, W., Healy, C. M., Conway, D. I., Robinson, M., Canova, C., Holcátová, I., Richiardi, L., Znaor, A., Pring, M., Thomas, S., Hayes, D. N., Liu, G., Hung, R. J., Brennan, P., Olshan, A. F., Virani, S., and Waterboer, T.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:International Journal of Cancer
Publisher:Wiley
ISSN:0020-7136
ISSN (Online):1097-0215
Published Online:11 September 2023
Copyright Holders:Copyright: © 2023 The Authors
First Published:First published in International Journal of Cancer 154(2):389-402
Publisher Policy:Reproduced under a Creative Commons licence
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record